BELMONT, Calif., May 8, 2012 /PRNewswire/ -- Phalanx Biotech Group, a global genomic products and service provider, announces today the completion of manufacturing and testing for a proprietary targeted chromosomal microarray (CMA) designed specifically for prenatal and postnatal detection of microdeletions and microduplications related to a spectrum of congenital disorders, especially developmental and intellectual delay disorders. CytoOneArray® is capable of detecting 264 clinically confirmed disease regions and 41 subtelomere regions.
“Extensive testing from our CytoOneArray® manufacturing campaign demonstrates a quality product with high sensitivity, robustness, and reproducibility. We are extremely excited about offering our focused CMA at the time when cytogeneticists are adopting chromosomal microarray as a first-tier clinical diagnostic test,” said Shengwan Lee, Ph.D., President and CEO. “As the first in a series of CMA microarrays, Phalanx will continue to expand its line of clinical diagnostic products by leveraging its high performance microarray technology and innovative manufacturing processes.”
CytoOneArray® resulted from extensive collaborations between leading cytogeneticists in Taiwan and Phalanx Biotech Group. Through a comprehensive curation process of current, peer-reviewed and clinically confirmed disease regions, the Phalanx team designed probes to cover 90% of published microdeletions and microduplications associated with developmental and intellectual delay disorders.
About Phalanx Biotech Group
Phalanx Biotech Group, with operations in California, Taiwan and China, provides genomics research products and services worldwide to academic, clinical, pharmaceutical and biotech communities. Built on world-class, integrated-chip foundry technology, Phalanx Biotech has developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes (human, mouse, rat, yeast and rice), microRNA (human, mouse, rat and plants), and custom targets. Our highly-trained service specialists provide a comprehensive offering of gene expression and microRNA expression profiling services for biomarker discovery including sample preparation, expression analysis, and qPCR validation. For more information about our products and services, please visit our website at www.OneArray.com.
Contact
Vivien Mak, Ph.D., 1-650-320-8669 ext 103
vmak@onearray.com
SOURCE Phalanx Biotech Group
